Technology Appraisal Committee Meeting (Committee B)

Minutes: Confirmed

Date and Time: Wednesday, 22 February 2017, 10am to 5pm

Venue: National Institute for Health and Care Excellence
10 Spring Gardens
London
SW1A 2BU

Present: 1. Dr Amanda Adler Present for all notes
2. Dr Ray Armstrong Present for all notes
3. Professor John Cairns Present for all notes
4. Mr Mark Chapman Present for all notes
5. Dr Sumeet Gupta Present for all notes
6. Dr Sanjay Kinra Present for all notes
7. Dr Miriam McCarthy Present for all notes
8. Mr Christopher O'Regan Present for notes 1 to 19
9. Dr Sanjeev Patel Present for all notes
10. Dr Danielle Preedy Present for all notes
11. Professor Ken Stein Present for all notes
12. Dr Nicky Welton Present for all notes
13. Mr Nigel Westwood Present for all notes
14. Dr Stuart Williams Present for all notes

In attendance:

Bashama Anjum Administrator, National Institute for Health and Care Excellence Present for all notes
Meindert Boysen Programme Director, National Institute for Health and Care Excellence Present for all notes
Ahmed Elsada Technical Advisor, Technology Appraisals, NICE Present for notes 1 to 19
Liv Gualda Project Manager, National Institute for Health and Care Excellence Present for all notes
Melinda Goodell Associate Director, National Institute for Health and Care Excellence Present for all notes
Jasdeep Hayre Technical Adviser, National Institute for Health and Clinical Present for notes 19 to 32
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Present For Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Maloney</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>1 to 19</td>
</tr>
<tr>
<td>Thomas Strong</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>19 to 32</td>
</tr>
<tr>
<td>Irina Voicechovskaja</td>
<td>Technical Analyst, National Institute for Health and Care Excellence</td>
<td>19 to 32</td>
</tr>
<tr>
<td>Mariana Bacelar</td>
<td>Evidence Review Group, Senior Health Economist, BMJ Evidence</td>
<td>1 to 19</td>
</tr>
<tr>
<td>Samantha Barton</td>
<td>Evidence Review Group, Evidence team lead BMJ Evidence</td>
<td>1 to 19</td>
</tr>
<tr>
<td>Steve Edwards</td>
<td>Evidence Review Group, Head of Health BMJ Evidence</td>
<td>1 to 19</td>
</tr>
<tr>
<td>Mark Rodgers</td>
<td>Evidence Review Group, Research Fellow, Centre for Reviews and Dissemination, University of York</td>
<td>19 to 32</td>
</tr>
<tr>
<td>Claire Rothery</td>
<td>Evidence Review Group, Senior Research Fellow, Centre for Reviews and Dissemination, University of York</td>
<td>19 to 32</td>
</tr>
<tr>
<td>Dr John Ashcroft</td>
<td>Consultant Haematologist, Mid Yorkshire NHS Trust/Leeds Teaching Hospitals NHS Trust, nominated by UK Myeloma Forum</td>
<td>1 to 19</td>
</tr>
<tr>
<td>David Chandler</td>
<td>Patient expert, Chief Executive, Psoriasis and Psoriatic Arthritis Alliance</td>
<td>19 to 32</td>
</tr>
<tr>
<td>Dr Karolina Gholam</td>
<td>Consultant Paediatric Dermatologist, Great Ormond Street Hospital, nominated by AbbVie</td>
<td>19 to 32</td>
</tr>
<tr>
<td>Eric Low</td>
<td>Chief Executive Myeloma UK, nominated by Myeloma UK</td>
<td>1 to 19</td>
</tr>
<tr>
<td>Barry Neville</td>
<td>Patient expert, nominated by Myeloma UK</td>
<td>1 to 19</td>
</tr>
<tr>
<td>Dr Cathy Williams</td>
<td>Consultant</td>
<td>1 to 19</td>
</tr>
</tbody>
</table>
Haematologist, Centre for Clinical Haematology, Nottingham University Hospitals, nominated by Janssen

**Non-public observers:**

<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Present for all notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Helen Barnett</td>
<td>Senior Medical Editor, NICE</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Luke Cowie</td>
<td>Scientific Adviser - Patient Preferences, NICE</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Heidi Livingstone</td>
<td>Senior Public Involvement Advisor, Communications, NICE</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Joshua South</td>
<td>Coordinator, National Institute for Health and Clinical Excellence</td>
<td>Present for all notes</td>
</tr>
</tbody>
</table>
Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933] and adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

2. The Chair welcomed Dr Stuart Williams to their first meeting as a member of the Appraisal Committee.


4. Apologies were received from Dr Mark Glover, Mrs Anne Joshua, Dr Neil Losson, and Dr Nigel De Kare Silver.

Any other Business

5. None

Notes from the last meeting

6. Minutes from November, 2016 and January 2017 committee meetings were presented to the committee.

Appraisal of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933]
Part 1 – Open session

7. The Chair welcomed the invited experts: Dr John Ashcroft, Mariana Bacelar, Samantha Barton, Steve Edwards, Eric Low, Barry Neville, Dr Cathy Williams to the meeting and they introduced themselves to the Committee.

8. The Chair welcomed company representatives from Janssen to the meeting.

9. The Chair asked all Committee members to declare any relevant interests

   9.1. Dr Amanda Adler, Dr Ray Armstrong, Professor John Cairns, Mr Mark Chapman, Dr Sumeet Gupta, Dr Sanjay Kinra, Dr Miriam McCarthy, Mr Christopher O'Regan, Dr Sanjeev Patel, Dr Danielle Preedy, Professor Ken Stein, Dr Nicky Welton, Mr Nigel Westwood, Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933].

10. The Chair asked all NICE Staff to declare any relevant interests.
10.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933].

11. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

11.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933].

12. The Chair introduced the lead team, Professor John Cairns, Dr Sumeet Gupta, and Dr Danielle Preedy who gave presentations on the clinical effectiveness and cost effectiveness of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933].

13. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

14. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

15. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

16. Discussion on confidential information continued. This information was supplied by the company.

17. The Committee continued to discuss the clinical and cost effectiveness of daratumumab monotherapy for treating relapsed and refractory multiple myeloma [ID933].

18. The committee decision was based on consensus.

19. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Appraisal of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

Part 1 – Open session
20. The Chair welcomed the invited expert: David Chandler and Dr Karolina Gholam to the meeting and they introduced themselves to the Committee.

21. The Chair welcomed company representatives from AbbVie to the meeting.

22. The Chair asked all Committee members to declare any relevant interests

Dr Amanda Adler, Dr Ray Armstrong, Professor John Cairns, Mr Mark Chapman, Dr Sumeet Gupta, Dr Sanjay Kinra, Dr Miriam McCarthy, Dr Sanjeev Patel, Dr Danielle Preedy, Professor Ken Stein, Dr Nicky Welton, Mr Nigel Westwood, Dr Stuart Williams all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

22.1. Christopher O'Regan declared a personal specific financial interest as his team had produced the assessment report for this appraisal, which he was directly involved.

9.3.1 It was agreed that this declaration would prevent Christopher O'Regan from participating in this section of the meeting.

23. The Chair asked all NICE Staff to declare any relevant interests.

23.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

24. The Chair asked all other invited guests (assessment group/ERG and invited experts, not including observers) to declare their relevant interests.

24.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

25. The Chair introduced the lead team, Dr Sanjay Kinra and Dr Miriam McCarthy, Mr Nigel Westwood who gave presentations on the clinical effectiveness and cost effectiveness of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

26. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.
27. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

28. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

29. Discussion on confidential information continued. This information was supplied by the company.

30. The Committee continued to discuss the clinical and cost effectiveness of adalimumab, etanercept and ustekinumab for treating severe, chronic plaque psoriasis in children and young people [ID854].

31. The committee decision was based on consensus.

32. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

Thursday, 23 March 2017, 10am to 5pm at ETC venues, Prospero House, 241 Borough High Street, London SE1 1GA.